|
Integrated safety summary of single-agent mirvetuximab soravtansine in patients with folate receptor α (FRα)-positive recurrent ovarian cancer: Phase 1 and 3 clinical trials. |
| |
|
Leadership - GOG Partners; NRG Oncology (Inst) |
Honoraria - Great Debates and Updates; Physicans' Education Resource; Prime Oncology; Research To Practice |
Consulting or Advisory Role - Alkermes (Inst); Aravive; AstraZeneca; Blueprint Medicines (Inst); Eisai; Genentech/Roche; GlaxoSmithKline/Tesaro (Inst); I-Mab (Inst); Immunogen; InxMed (Inst); Merck; Mereo BioPharma; Mereo BioPharma (Inst); Mersana (Inst); Myriad Genetics; Novartis; Onconova Therapeutics; OncXerna Therapeutics; TESARO (Inst); Vavotar Life Sciences; VBL Therapeutics |
Research Funding - Abbvie/Stemcentrx (Inst); Advaxis (Inst); Agenus (Inst); Amgen (Inst); artios (Inst); AstraZeneca (Inst); Bayer (Inst); Bolt Biotherapeutics (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); cyteir (Inst); Daiichi Sankyo/Lilly (Inst); Forty Seven (Inst); Genentech (Inst); Immunocore (Inst); Immunogen (Inst); Lilly (Inst); Lilly Foundation (Inst); Merck (Inst); Novartis Pharmaceuticals UK Ltd. (Inst); Novogen (Inst); PTC Therapeutics (Inst); Regeneron (Inst); Stem CentRx (Inst); Takeda (Inst); Tesaro (Inst); Verastem (Inst) |
Patents, Royalties, Other Intellectual Property - UpToDate |
Other Relationship - GOG Partners (Inst) |
| |
|
Consulting or Advisory Role - Amgen; AstraZeneca; Clovis Oncology; Corcept Therapeutics; Genmab; GlaxoSmithKline; Immunogen; Merck Serono; MSD; Oncoinvest; PharmaMar; Seagen; Sutro Biopharma |
Speakers' Bureau - AstraZeneca; Clovis Oncology; GlaxoSmithKline; MSD; PharmaMar |
Research Funding - AstraZeneca (Inst); Clovis Oncology (Inst); Clovis Oncology (Inst); Genmab (Inst); GlaxoSmithKline (Inst); GlaxoSmithKline (Inst); Immunogen (Inst); Incyte (Inst); MSD (Inst); MSD (Inst); Novartis (Inst); PharmaMar (Inst); Roche (Inst); Seagen (Inst) |
Travel, Accommodations, Expenses - AstraZeneca; Clovis Oncology; GlaxoSmithKline; GlaxoSmithKline; PharmaMar; Roche |
(OPTIONAL) Uncompensated Relationships - Gynecological Cancer InterGroup |
| |
|
Consulting or Advisory Role - AGENUS; Amgen; AstraZeneca; Clovis Oncology; Corcept Therapeutics; Deciphera; Eisai; EMD Serono; Genmab; GlaxoSmithKline; Immunogen; ITeos Therapeutics; Medison; Merck Sharp & Dohme; Mersana; Novocure; PharmaMar; prIME Oncology; Roche; Roche; Shattuck Labs; Sutro Biopharma; Tesaro |
Research Funding - Abbvie (Inst); Ability Pharma (Inst); Advaxis (Inst); Aeterna Zentaris (Inst); Agenus (Inst); Aprea Therapeutics (Inst); AstraZeneca (Inst); BeiGene (Inst); Belgian Gynaecological Oncology Group (Inst); Bristol-Myers Squibb International Corporation (BMS) (Inst); Clovis Oncology (Inst); Corcept Therapeutics (Inst); Eisai (Inst); Immunogen (Inst); Iovance Biotherapeutics (Inst); Iovance Biotherapeutics (Inst); Lilly (Inst); Medimmune (Inst); Merck (Inst); Merck Sharp & Dohme (Inst); Merck Sharp & Dohme (Inst); Mundipharma Research (Inst); Novartis Farmacéutica (Inst); Regeneron (Inst); Roche (Inst); Seagen (Inst); Seagen (Inst); Sutro Biopharma (Inst); Tesaro (Inst); Verastem (Inst) |
Travel, Accommodations, Expenses - AstraZeneca; Clovis Oncology; PharmaMar; Roche |
| |
|
(OPTIONAL) Uncompensated Relationships - Ozmosis Research |
| |
|
Employment - Sarepta Therapeutics (I) |
Honoraria - Advaxis; Amgen; AstraZeneca; Clovis Oncology; Eisai; GlaxoSmithKline; Immunogen; mersana; MSD Oncology; Novartis; Nuvation Bio; Pfizer; Pfizer; Roche/Genentech; Tesaro |
Consulting or Advisory Role - Advaxis; AstraZeneca; Clovis Oncology; Eisai; GlaxoSmithKline; Immunogen; mersana; MSD Oncology; Nuvation Bio; Pfizer; Pfizer; Roche/Genentech; Tesaro |
| |
|
Consulting or Advisory Role - AstraZeneca (Inst); Eisai Europe (Inst); GlaxoSmithKline (Inst); MSD/Merck (Inst); OncXerna Therapeutics (Inst) |
Travel, Accommodations, Expenses - AstraZeneca (Inst); Immunogen (Inst); MSD/Merck (Inst); PharmaMar (Inst) |
| |
|
Consulting or Advisory Role - Abbvie; Agenus; Ambry Genetics; Arcus Biosciences; Arquer Diagnostics; AstraZeneca; Atossa Therapeutics; BBI Healthcare; Celsion; Clovis Oncology; Eisai; Elevar Therapeutics; Genelux; Genentech/Roche; GlaxoSmithKline; GOG Foundation; Immunogen; InxMed; Iovance Biotherapeutics; Janssen Oncology; Laekna Therapeutics; Leap Therapeutics; Marker Therapeutics; Myriad Genetics; Novartis; Novocure; Novocure; Onconova Therapeutics; OncoQuest; Regeneron; Roche; Rubius Therapeutics; Seagen; Sorrento Therapeutics; Sutro Biopharma; Takeda; Tarveda Therapeutics; Tesaro; Toray Industries; Translational Genomics Research Institute; VBL Therapeutics; Vincerx Pharma |
Research Funding - Abbvie (Inst); Abbvie/Stemcentrx (Inst); Acerta Pharma (Inst); Advaxis (Inst); Ajinomoto (Inst); Ajinomoto (Inst); Amgen (Inst); Arcus Biosciences (Inst); Array BioPharma (Inst); AstraZeneca (Inst); BBI Healthcare (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Cerulean Pharma (Inst); Clovis Oncology (Inst); Deciphera (Inst); Eisai (Inst); EMD Serono (Inst); EMD Serono (Inst); Ergomed (Inst); Exelixis (Inst); Genentech/Roche (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Immunogen (Inst); Immunogen (Inst); Incyte (Inst); Iovance Biotherapeutics (Inst); Janssen Research & Development (Inst); Karyopharm Therapeutics (Inst); Leap Therapeutics (Inst); Ludwig Institute for Cancer Research (Inst); Merck (Inst); Mersana (Inst); Novartis (Inst); NovoCure (Inst); OncoQuest (Inst); Pfizer (Inst); PharmaMar (Inst); Precision Therapeutics (Inst); Regeneron (Inst); Roche (Inst); Sanofi (Inst); Seagen (Inst); Seagen (Inst); Sumitomo Dainippon Pharma Oncology, Inc. (Inst); Sutro Biopharma (Inst); Tesaro (Inst); TRACON Pharma (Inst); Verastem (Inst) |
| |
|
Honoraria - Amgen; AstraZeneca; Clovis Oncology; GlaxoSmithKline; Immunogen; Mersana; MSD Oncology; Pfizer; Roche; Takeda |
Consulting or Advisory Role - Amgen; AstraZeneca; GenMab; GlaxoSmithKline; Immunogen; Merck Serono; Mersana; MSD Oncology; OncXerna Therapeutics; Seagen; Shattuck Labs |
Research Funding - AstraZeneca (Inst); GlaxoSmithKline (Inst) |
| |
|
Honoraria - Janssen Oncology |
Travel, Accommodations, Expenses - Ipsen; Pfizer |
| |
|
No Relationships to Disclose |
| |
|
Speakers' Bureau - AstraZeneca; Clovis Oncology; GlaxoSmithKline; Merck |
Research Funding - Lilly (Inst); Merck (Inst) |
| |
|
Consulting or Advisory Role - AstraZeneca (Inst); MSD Oncology (Inst); MSD vaccin (Inst); Onxeo (Inst); PharmaMar (Inst) |
Research Funding - Onxeo (Inst); PharmaMar (Inst) |
Expert Testimony - Clovis Oncology (Inst); Onxeo (Inst); Roche |
Travel, Accommodations, Expenses - AstraZeneca; GlaxoSmithKline; MSD Oncology; OSE Immunotherapeutics; Roche |
| |
|
|
Stock and Other Ownership Interests - Exact Sciences; Lilly |
| |
|
|
Stock and Other Ownership Interests - Immunogen |
| |
|
Consulting or Advisory Role - ImmunoGen |
| |
|
|
|
Stock and Other Ownership Interests - McKesson |
Consulting or Advisory Role - Abbvie; Abbvie/Stemcentrx; Agenus; Alkermes; AstraZeneca/MedImmune; Clovis Oncology; Genentech/Roche; Genmab; Gradalis; Immunogen; Merck; Merck; Novocure; Oncolytics; OncoMed; OncXerna Therapeutics; Regeneron; Sotio; Tesaro |
Research Funding - Abbott/AbbVie; Amgen (Inst); Array BioPharma; AstraZeneca/MedImmune; Clovis Oncology; Esperance Pharmaceuticals; Immunogen (Inst); Johnson & Johnson; Lilly (Inst); Merck; Mirati Therapeutics (Inst); Pfizer (Inst); Regeneron (Inst); Roche/Genentech |
Travel, Accommodations, Expenses - Array BioPharma; AstraZeneca/MedImmune; Clovis Oncology; Clovis Oncology; GOG Foundation; Merck; Research to Practice; Roche/Genentech; Sotio; Vaniam Group |
| |
|
Honoraria - Advaxis; Alkermes; Symphogen |
Consulting or Advisory Role - Agenus; AstraZeneca; Blueprint Medicines; GlaxoSmithKline; Merck; NextCure; Novartis; Trillium Therapeutics |
Research Funding - Fujifilm; Immunogen; Leap Therapeutics; Merck; Mersana; Novartis; SQZ Biotech; Syndax; Tesaro |
Travel, Accommodations, Expenses - AstraZeneca |